Effects of 3-hydroxy-3-methyglutaryl-coenzyme A(HMG-CoA)reductase inhibitor upon the serum high sensitive CRP in the post-ischemic patients with hyperlipidemia during the prospective study of J-STARS.

INTERVENTION: Patients will be randomized into the group receiving pravastatin or that having no statin. Intervention consists of pravastain treatment (10mg/day), that will start within 1 month of entry and continue until the end of study or the endpoints. Non‐administration group of pravastatin (control group) CONDITION: Ischemic stroke PRIMARY OUTCOME: Serum high sensitive CRP concentration SECONDARY OUTCOME: Recurrent stroke INCLUSION CRITERIA: 1) Ischemic stroke except for cardiogenic embolism, from 1 month to 3 years after onset 2) 45‐80 years old 3) Patients diagnosed as hyperlipidemia 4) No prescription of statin within previous 30 days 5) The total cholesterol level of 180‐240mg/dl within previous 30 days 6) Allowed to visit outpatient department 7) Informed consent on the form filled out by the patient.